Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.
about
Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancersDifferential roles of uPAR in peritoneal ovarian carcinomatosisInhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach.Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment.Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18.Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumorsLow-dose glucocorticoids suppresses ovarian tumor growth and metastasis in an immunocompetent syngeneic mouse model.The interplay between surfaces and soluble factors define the immunologic and angiogenic properties of myeloid dendritic cells.Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents.Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo.Development of a syngeneic mouse model of epithelial ovarian cancer.Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancerCancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer.T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression.An immunocompetent, orthotopic mouse model of epithelial ovarian cancer utilizing tissue engineered tumor cell sheetsDownregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer.Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy.Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis.Effects of nerve growth factor (NGF) on blood vessels area and expression of the angiogenic factors VEGF and TGFbeta1 in the rat ovaryInvolvement of endothelial CD44 during in vivo angiogenesis.Generation and characterization of an ascitogenic mesothelin-expressing tumor model.Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancerSuppression of epithelial ovarian cancer invasion into the omentum by 1α,25-dihydroxyvitamin D3 and its receptorVascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.A homeobox gene related to Drosophila distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis.Adhesion to substrates induces dendritic cell endothelization and decreases immunological response.Angiogenesis in normal and neoplastic ovaries.Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasisShould tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer.Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cellsWhole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells.Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.Angiogenesis in platelet endothelial cell adhesion molecule-1-null miceIn vivo dendritic cell tracking using fluorescence lifetime imaging and near-infrared-emissive polymersomes.Migration-inducing gene 7 promotes tumorigenesis and angiogenesis and independently predicts poor prognosis of epithelial ovarian cancer.
P2860
Q21562662-6B226D41-D6E1-4EEB-9F50-4AB40D3899EEQ30426956-43DC6CFE-A8F1-44AD-8E36-08535692FA97Q33223885-A6947EB9-41D0-4DBE-9932-004CCF93F7BBQ33323364-C564BEC7-9308-4062-A4D2-FBC7654A9A0CQ33552702-2EF80AE8-91B8-4B20-9C14-7E36C00C4F0DQ33765767-70ED2FED-A8C7-4956-BB85-F60BFA7AA764Q33773081-A1F258A1-F999-44BA-B864-449D847D48FCQ33924531-BE282896-7161-47C9-982B-AABDA6648C46Q33994590-7B08DC10-D2A1-4DCA-B042-E56A593E1D83Q34139923-CDF7B17B-4956-47F1-8CEF-A7EEF15DFCA1Q34268119-1711AEC1-1337-42A6-83BD-554CFC43E5B9Q34282708-AD116C0A-385E-4606-B4BD-189F9D2BB2CFQ34781970-23DFA8B2-3B9A-47A2-B74F-2654A2C7AB1AQ34887528-4E2EBE78-FBB6-4007-93B0-51CF2DFE6F34Q34893030-6B4DC1DD-7BD0-4B57-A9C5-EF6AB5F65726Q34919480-14A534C2-EA6E-4EF4-A120-62D666439975Q34964017-EC4B3C48-D471-4EBB-BBA4-F365115E02A1Q35053993-2BC0FD05-A442-47BE-8D54-3E235EC3A0C9Q35094484-4368A60B-6D60-4176-92A9-E02EBF0371A9Q35173690-3C8CB029-7ED0-4C52-9C62-DE3AF040A7E1Q35221868-850C0EB6-7C6C-4661-9E2D-59390E0D3123Q35236067-023811EB-572A-4E60-BE97-73B63C200F0AQ35572426-20EF7DF2-4D72-48C5-A8BE-FF360F4541C0Q35737779-82C1F106-04BC-4A40-81F0-42A961D14B58Q35750289-447D2D6A-EFDE-4F25-85DF-50AE5B819C4AQ35757194-EF49731E-232D-4614-95AC-6E4FBC66E756Q35920573-75D0C689-AB79-4062-9202-C0FEA3D848B2Q35954103-F5D082BC-31C2-4231-AEBD-6850AD42E657Q36122605-4B74141D-4042-4D5F-96E3-3803FEE362D0Q36146867-620619D5-D5FC-4433-829F-7FF2832F3B95Q36279903-4F6A5D29-CEC3-4FCE-9563-23BFEC29CD93Q36322698-D5A9914A-C39D-4E71-8703-F2F45D74C46AQ36449367-D433F7FD-EF30-4421-ADB4-3C9BE3AC00F4Q36608738-71C57C9D-158C-43EC-ABE7-EABB69AFCDC0Q36691357-27D7D77D-62AC-4E90-80D8-E832D467FAF1Q36941194-D25A8ECA-D765-4EA2-A120-FD4B7DB9E7B8Q36958112-B70F1406-1418-4199-868D-7451C56B0722Q37278535-F697CD0B-F52B-4E36-837E-FC1E64E51CC6Q37314596-95B1E4B6-F032-4F95-BCFF-91FBBAEA51B2Q37317324-C5ACDD30-AAEC-4BAA-87E1-992FEB1341CF
P2860
Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Generation of a syngeneic mous ...... h factor in ovarian carcinoma.
@ast
Generation of a syngeneic mous ...... h factor in ovarian carcinoma.
@en
type
label
Generation of a syngeneic mous ...... h factor in ovarian carcinoma.
@ast
Generation of a syngeneic mous ...... h factor in ovarian carcinoma.
@en
prefLabel
Generation of a syngeneic mous ...... h factor in ovarian carcinoma.
@ast
Generation of a syngeneic mous ...... h factor in ovarian carcinoma.
@en
P2093
P2860
P1476
Generation of a syngeneic mous ...... th factor in ovarian carcinoma
@en
P2093
Alisha Mohamed
David Allman
Jose-Ramon Conejo Garcia
Stephen C Rubin
P2860
P304
P356
10.1016/S0002-9440(10)64505-1
P407
P577
2002-12-01T00:00:00Z